Developing long-acting HIV treatments for children
Dose flexible ultra-long-acting prodrug formulations for pediatric populations
This study is testing a new injectable medicine for kids with HIV-1 that they would only need to get every six months, making it easier and more effective than taking daily pills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11055903 on NIH RePORTER |
What this research studies
This research focuses on creating a new injectable medication for children living with HIV-1 that can be administered every six months. By using a novel formulation of a drug called bictegravir, the goal is to provide a more effective and convenient treatment option compared to daily oral medications. The study aims to address the challenges of current treatments, which can be unpredictable in children due to their changing pharmacokinetics. The innovative approach seeks to enhance viral suppression rates and improve adherence to treatment among pediatric patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0 to 11 years who are living with HIV-1 infection.
Not a fit: Patients who are not living with HIV-1 or are older than 11 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient treatment option for children with HIV-1, potentially improving their health outcomes.
How similar studies have performed: Other research has shown promise in developing long-acting formulations for HIV treatment, indicating that this approach has potential for success.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Edagwa, Benson — University of Nebraska Medical Center
- Study coordinator: Edagwa, Benson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.